Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The Massachusetts-based cancer stem cell company has struck two deals in as many days in an effort to move compounds into the clinic for various types of cancers and multiple targets.


Related Content

Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans
Start-Up Quarterly Statistics, Q3 2012
Verastem Joins The Public Markets With A Strong IPO


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts